Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Completed
This is a randomized, open-label, multi-center, phase 2 study of RCHOP with or without VELCADE in adult patients with previously untreated non-(Germinal B-Cell-like) GCB Diffuse Large B-cell Lymphoma (DLBCL). The study will determine whether the addition of VELCADE to RCHOP improves progression-free survival (PFS) in patients with non-GCB DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2016
Locations: Raleigh Hematology Oncology Associates P.C., Raleigh, North Carolina
Conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Adj TC + Herceptin Early Stage Breast Cancer
Completed
The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
09/15/2016
Locations: Cancer Centers of North Carolina, Raleigh, North Carolina
Conditions: Breast Cancer
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Completed
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2011
Locations: Pfizer Investigational Site, Burlington, North Carolina +2 locations
Conditions: Adenocarcinoma